Profound Medical Q3 Revenue Jumps 89% to Record $10M

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced on October 7, 2026 that it expects preliminary unaudited third-quarter revenue of $9.8 million to $10.0 million, roughly 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million. The Toronto-based interventional MRI device maker said the figure would mark its highest quarterly revenue on record, up about 85% to 89% year over year from $5.3 million and some 292% to 300% sequentially from $2.5 million.

Context — Why the Profound Medical Revenue Beat Matters Now

Profound's prior-year comparison is the $5.3 million it booked in the third quarter of 2025. The sequential base is the $2.5 million reported for the second quarter of 2026. Both figures come from the company's own release, and the gap between them and the new guidance is what makes this quarter unusual.

The second-quarter base is the striking number. A jump from $2.5 million to a midpoint of $9.9 million implies the company roughly quadrupled revenue in a single quarter, a pace rarely seen from a commercial-stage device maker with an installed base rather than a one-off product launch.

Profound attributes the step-up to broader commercial activity, not a single order. Chief executive and chairman Arun Menawat said the expected increase "represents a historic milestone for Profound," pointing to what he described as increased activity across the existing installed base and new customer accounts.

The company sells two platforms: TULSA-PRO, which uses MRI guidance for incision-free prostate ablation, and Sonalleve, an MRI-guided therapy for bone metastases pain palliation, desmoid tumors, osteoid osteoma and gynecologic conditions including uterine fibroids and adenomyosis. Both are approved across major markets, and revenue is therefore spread across geographies rather than concentrated in one regulator's territory.

That matters for the read-through. Device companies that grow through utilization of already-installed systems convert incremental procedures into high-margin revenue, because the capital equipment has already been paid for. Profound's guidance that gross margin will again exceed 70% is consistent with that mix, though the company did not break out how much of the quarter came from consumables versus system sales.

Data — What the Numbers Show

The headline comparison is consensus. Bloomberg's mean analyst estimate stood at $6.78 million as of 9:02 a.m. ET on October 7, 2026, the company said, and the guided range sits roughly 45% to 47% above it. Profound noted that it does not endorse, adopt or control third-party consensus estimates.

Metric	Q3-2025	Q2-2026	Q3-2026 guidance
Revenue	$5.3M	$2.5M	$9.8M-$10.0M
Gross margin	not disclosed	not disclosed	above 70%

On a year-over-year basis, the guided range implies growth of approximately 85% to 89%. Sequentially, the implied increase is approximately 292% to 300%. Both percentages are the company's own.

Gross margin is the second number that matters. Profound said Q3-2026 gross margin is again expected to exceed 70%, language that signals the prior quarter already cleared that threshold even as absolute revenue was low. A company holding a 70%-plus gross margin while revenue scales is a different earnings profile from one buying growth with discounts.

The report gives no peer comparison and no sector benchmark. Profound competes in image-guided ablation, but the release names no competitor, no market-share figure and no total addressable market estimate. Those gaps are worth flagging because the revenue beat is large enough that readers will want context the company did not supply.

All figures are preliminary and unaudited. Profound said actual revenues may differ from the guidance range.

Analysis — What It Means for Medical Device Markets

The immediate read is that Profound's commercial build-out is converting faster than the sell side modeled. A 45%-plus beat against consensus is not a rounding error; it suggests analysts underestimated either procedure volumes per installed system or the number of new accounts going live in the quarter. Menawat's reference to the installed base points toward utilization as the driver.

The second-order effect runs through the iMRI therapy niche. If TULSA-PRO utilization is rising, the constraint on growth shifts from physician adoption to reimbursement and referral pathways, neither of which the company quantified. Investors in the broader surgical robotics and prostate care space will read this as evidence that incision-free ablation is taking share, though the release offers no procedure counts to confirm that.

There is a counter-argument worth holding. A single quarter does not establish a trend, and the sequential jump is so large that it invites questions about pull-forward, one-time system placements or revenue recognition timing. Profound did not disclose how many systems it sold, how many procedures were performed, or whether any portion of the quarter was non-recurring.

Positioning is the other angle. A beat of this size against a $6.78 million consensus typically forces short interest and underweight positioning to unwind, and it raises the bar for the November print. The report gives no short interest, no ownership data and no price level, so the magnitude of any squeeze cannot be sized from the available facts.

Outlook — What to Watch Next

The next hard catalyst is dated. Profound said it will report full third-quarter 2026 financial results after market close on Thursday, November 5, 2026, and will host a conference call at 4:30 p.m. ET the same day to review results and discuss business developments.

That call is where the open questions get answered. Investors should look for procedure volume, system placement counts and a breakdown of consumable versus capital revenue, none of which the preliminary release provided. Gross margin detail will show whether the 70%-plus level is holding as revenue scales.

A second item to watch is whether the company updates its commercial strategy language. Menawat said Profound remains focused on supporting customer adoption, increasing utilization of the installed base and building a profitable growth company over the long term. Any shift in that framing on November 5 would matter more than the headline number.

No price levels, moving averages or valuation multiples appear in the report, so there are no technical thresholds to cite. The relevant threshold is operational: whether the fourth quarter holds anywhere near the third-quarter run rate.

Frequently Asked Questions

What does Profound Medical's preliminary Q3-2026 revenue mean for retail investors?

It means the company expects to report revenue far above what analysts modeled, which changes the near-term earnings picture. The guided $9.8 million to $10.0 million range is roughly 45% to 47% above the $6.78 million Bloomberg consensus and about 85% to 89% above the year-ago quarter. Investors should note the figures are preliminary and unaudited, and that Profound does not endorse third-party consensus estimates.

Why did Profound Medical revenue jump so much sequentially?

The company attributed the increase to greater commercial activity across its installed base and new customer accounts. Sequential growth of approximately 292% to 300% against a $2.5 million second-quarter base is unusually steep. Profound did not disclose procedure volumes, system placements or any one-time revenue component, so the precise mix behind the jump remains unconfirmed until the November 5 earnings call.

What happens next for Profound Medical stock?

The next scheduled event is the full third-quarter results release after market close on Thursday, November 5, 2026, followed by a conference call at 4:30 p.m. ET. That disclosure should include procedure counts, system sales and gross margin detail. The report provides no price levels or valuation figures, so the key thing to watch is whether the fourth quarter sustains the third-quarter run rate.

Bottom Line

Profound Medical guided to record quarterly revenue roughly 46% above consensus, and the November 5 call must show the jump is repeatable.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.